What is the Return on Assets (ROA) of EyeGene this year?
The Return on Assets (ROA) of EyeGene is -0.27 undefined this year.
EyeGene ROA 2024
EyeGene ROA
-0.27
Ticker
185490.KQ
ISIN
KR7185490000
In 2024, EyeGene's return on assets (ROA) was -0.27, a -16.3% increase from the -0.32 ROA in the previous year.
EyeGene Aktienanalyse
What does EyeGene do?
EyeGene Inc is a biotech company focused on the discovery, development, and commercialization of treatment options for rare eye diseases. EyeGene ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding EyeGene's Return on Assets (ROA)
EyeGene's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing EyeGene's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider EyeGene's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in EyeGene’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about EyeGene stock
What was the ROA of EyeGene compared to the previous year?
The ROA of EyeGene has increased by -16.3% compared to the previous year.
What consequences do high ROA have for investors of EyeGene?
A high ROA is advantageous for investors of EyeGene, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in EyeGene?
A low ROA can be unfavorable for investors of EyeGene as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of EyeGene affect the company?
An increase in ROA of EyeGene can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of EyeGene impact the company?
A reduction in the ROA of EyeGene can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of EyeGene?
Some factors that can influence the ROA of EyeGene include revenue, operating costs, asset structure, and industry average.
Why is the ROA of EyeGene important for investors?
The ROA of EyeGene is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can EyeGene take to improve ROA?
To improve ROA, EyeGene can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does EyeGene pay?
Over the past 12 months, EyeGene paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, EyeGene is expected to pay a dividend of 0 KRW.
What is the dividend yield of EyeGene?
The current dividend yield of EyeGene is .
When does EyeGene pay dividends?
EyeGene pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of EyeGene?
EyeGene paid dividends every year for the past 0 years.
What is the dividend of EyeGene?
For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.
In which sector is EyeGene located?
EyeGene is assigned to the 'Health' sector.
Wann musste ich die Aktien von EyeGene kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of EyeGene from 10/5/2024 amounting to 0 KRW, you needed to have the stock in your portfolio before the ex-date on 10/5/2024.
When did EyeGene pay the last dividend?
The last dividend was paid out on 10/5/2024.
What was the dividend of EyeGene in the year 2023?
In the year 2023, EyeGene distributed 0 KRW as dividends.
In which currency does EyeGene pay out the dividend?
The dividends of EyeGene are distributed in KRW.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von EyeGene
Our stock analysis for EyeGene Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of EyeGene Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
